Hamaguchi Masahide, Kawahito Yutaka, Tsubouchi Yasunori, Kohno Masataka, Yamamoto Aihiro, Ishino Hidetaka, Wada Makoto, Yoshikawa Toshikazu
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto, 602-8566, Japan.
Clin Rheumatol. 2007 Jul;26(7):1170-2. doi: 10.1007/s10067-006-0295-1. Epub 2006 Apr 14.
Conventional treatment is not standardized for hepatitis C virus-negative cryoglobulinemia, but corticosteroids, immunosuppressive agents, and plasma exchange typically improved the symptoms. Mizoribine is an immunosuppressive agent that was developed in Japan and has been found to inhibit the proliferation of lymphocytes, especially B cells. We have encountered an elder patient who had hepatitis C virus-negative, type II cryoglobulinemic vasculitis with leg purpura and skin ulcers. Her symptoms improved and cryoglobulin disappeared by the combination therapy of prednisolone and mizoribine. We speculate the action mechanism of this therapy is due to immunosuppressive effects including up-regulation of the efficacy of prednisolone by mizoribine.
对于丙型肝炎病毒阴性冷球蛋白血症，传统治疗并不规范，但使用皮质类固醇、免疫抑制剂和血浆置换通常可改善症状。咪唑立宾是一种在日本研发的免疫抑制剂，已发现其能抑制淋巴细胞尤其是B细胞的增殖。我们遇到了一位老年患者，患有丙型肝炎病毒阴性的II型冷球蛋白血症性血管炎，伴有腿部紫癜和皮肤溃疡。通过泼尼松龙和咪唑立宾联合治疗，她的症状得到改善，冷球蛋白消失。我们推测这种治疗的作用机制是由于免疫抑制作用，包括咪唑立宾上调泼尼松龙的疗效。
